Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. by Leandro Cerchietti, Christine Damm-Welk, Inga Vater, Wolfram Klapper, Lana Harder, Christiane Pott, Shao Ning Yang, Alfred Reiter, Reiner Siebert, Ari Melnick, Willi Woessmann

Get full text